GENSCRIPT BIO: Prosperous received new payments based on the licensing agreement with Lixin Pharmaceutical Technology
GENSCRIPT BIO announced that it received a new payment of approximately RMB 480 million (about USD 67.5 million) from Pengbo according to the licensing agreement with LiXin Pharmaceutical Technology. This is the second sublicense revenue related to the anti-PD-1 single-domain antibody. By October 14, 2025, Pengbo has cumulatively received approximately RMB 2 billion (about USD 284 million). This amount will enhance Pengbo's cash reserves and support new molecular discovery and development
According to the Zhitong Finance APP, GENSCRIPT BIO (01548) announced that it has received a new payment of approximately RMB 480 million (equivalent to about USD 67.5 million, net of withholding income tax) under the restated and amended licensing agreement. This payment is the second tranche of sublicensing revenue related to the licensed anti-PD-1 single-domain antibody under the restated and amended licensing agreement. The anti-PD-1 single-domain antibody is used in the development of the investigational PD-1/VEGF bispecific antibody LM-299, which has received approval for clinical research of new drugs.
As of October 14, 2025, GENSCRIPT BIO has cumulatively received approximately RMB 2 billion (equivalent to about USD 284 million, net of withholding income tax) under the restated and amended licensing agreement.
The receipt of these funds will further enhance GENSCRIPT BIO's cash reserves and support new molecular discovery and development
